Milner Institute hosts official opening of new Functional Genomics Screening Laboratory
Last week, we were delighted to launch the new Functional Genomics Screening Laboratory (FGSL) here at the Milner Therapeutics Institute in Cambridge, UK. The new lab will support world-class research and innovation in the rapidly advancing field of functional...
Milner Therapeutics Consortium renewed for five years
We are delighted that the Milner Therapeutics Consortium has been renewed until 2029, which will continue to provide opportunities for our academic and business communities to engage with pharma at an early stage. The Milner Therapeutics Consortium has been active...
Sir Tony Kouzarides attends Astex anniversary event, joining Lord Vallance to discuss opportunities in UK life sciences.
This week, Milner Institute Director Professor Sir Tony Kouzarides was pleased to attend a special event in celebration of Astex’s 25-year anniversary. The event showcased achievements the company has made since its formation, including three cancer drugs on the...
Milner Institute partners with Flagship Pioneering and CUHP to accelerate biotech research and innovation
We are delighted to announce a new collaboration with Flagship Pioneering and Cambridge University Health Partners (CUHP), to jointly advance breakthrough scientific research and technologies. The collaboration will focus on research and innovation and will enable...
Milner Executive Director Cathy Tralau-Stewart attends J.P. Morgan’s 43rd Annual Healthcare Conference
We are delighted that our Executive Director – Dr Cathy Tralau-Stewart – was invited to attend J.P. Morgan’s 43rd Annual Healthcare Conference this week. Cathy was pleased to connect with global industry leaders, emerging fast-growth companies, innovative...
Milner Institute welcomes affiliate network to first B2B Matchmaking Event
Last week, 40 Milner Affiliates joined our inaugural B2B Matchmaking Event here in Cambridge, bringing together a diverse range of start-ups, biotechs and larger services and CRO partners, as well as some of the pharma partners in the Milner Therapeutics Consortium....
Milner joins Cambridge-ARIA collaboration to create new technologies for transforming brain health
We are delighted that the Milner Therapeutics Institute (MTI) has joined a three-year collaboration with the science funding agency ARIA and multiple Cambridge partners, to engineer a new generation of neuro-technologies designed to treat depression, dementia, chronic...
Milner Institute awarded £7m to enable Functional Genomics Screening Laboratory as part of UK wide initiative
We’re delighted to announce that the Medical Research Council (MRC), in collaboration with the Biotechnology and Biological Sciences Research Council (BBSRC), awarded £7m to help establish the MRC-AstraZeneca-University of Cambridge joint Functional Genomics...